OVs effectively promote T-cell infiltration into the TME through genetic engineering to express chemokines (e.g., CXCL10, CCL5) or by disrupting physical tumor barriers, thereby enhancing anti-tumor immune responses [14]. The gene discussed is CXCL10; the disease is neoplasm.